Theranos Gets (Another) Bad Lab Report
Updated January 27, 2016, at 6:01 p.m.

The Wall Street Journal has more bad news about Theranos, the blood-testing startup that was once a Silicon Valley darling valued at $9 billion. The Journal reported today that laboratory violations at Theranos would put patients in “immediate jeopardy,” and disqualify the company from participating in the Medicare program.
On Monday, federal health inspectors found “serious deficiencies” at a Theranos lab. It’s not clear what those problems are, though the Journal says the issues are “far more severe” than ones detected in an inspection of the same laboratory in 2013. This comes after the Journal reported in October that Theranos was not yet able—as it claimed—to perform a wide range of lab tests on a pinprick-sized sample of blood.
Because Theranos has raised more than $400 million and made headlines for its eye-popping valuation, its stumbles have been a source of schadenfreude in Silicon Valley. But it would be a shame if its struggles obscured the fact that blood tests in general are justifiably hot right now: they can be used to glean remarkable new insights, even about tumors or other problems that show up only in minuscule amounts. That development won’t be derailed even if Theranos falls apart.
(Source: Wall Street Journal)
Keep Reading
Most Popular

Toronto wants to kill the smart city forever
The city wants to get right what Sidewalk Labs got so wrong.

Saudi Arabia plans to spend $1 billion a year discovering treatments to slow aging
The oil kingdom fears that its population is aging at an accelerated rate and hopes to test drugs to reverse the problem. First up might be the diabetes drug metformin.

Yann LeCun has a bold new vision for the future of AI
One of the godfathers of deep learning pulls together old ideas to sketch out a fresh path for AI, but raises as many questions as he answers.

The dark secret behind those cute AI-generated animal images
Google Brain has revealed its own image-making AI, called Imagen. But don't expect to see anything that isn't wholesome.
Stay connected

Get the latest updates from
MIT Technology Review
Discover special offers, top stories, upcoming events, and more.